Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study was a one-arm, retrospective cohort study that observed clinical psoriasis patients who received secukinumab treatment in Indonesia from the 01 August 2017 until the 31 October 2020. Patients' data were obtained from the medical records of a dermatology clinic in Jakarta, Indonesia. The primary endpoints were set at Week 16, and secondary endpoints at Weeks 16 and 52. At each endpoint, the study assessed effectiveness by measuring the proportion of psoriasis patients receiving secukinumab who achieved Psoriasis Area and Severity Index (PASI) 75 (at Week 8) and PASI 90 (at Weeks 16 and 52).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Secukinumab | Clinical psoriasis patients who received secukinumab treatment in Indonesia from 1 August 2017 to 31 October 2020. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients achieving Psoriasis Area and Severity Index (PASI) score <1, PASI score < 2, PASI score < 3, and PASI score < 5 at Week 16 | The PASI is used for assessing and grading the severity of psoriatic lesions and their response to therapy. PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a theoretic maximum of 72.0. | Week 16 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients achieving PASI 75 or higher response at Week 8 | PASI 75 response was defined as ≥ 75% improvement (reduction) in PASI score compared to baseline. | Week 8 |
| Percentage of patients achieving PASI 90 or higher response at Week 16 |
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mangga Besar Clinic | Jakarta | Indonesia |
Not provided
Not provided
Not provided
Not provided
PASI 90 response was defined as ≥ 90% improvement (reduction) in PASI score compared to baseline.
| Week 16 |
| Percentage of patients achieving PASI 90 or higher response at Week 52 | PASI 90 response was defined as ≥ 90% improvement (reduction) in PASI score compared to baseline. | Week 52 |
| Number of injections needed to achieve at least PASI 90 | PASI 90 response was defined as ≥ 90% improvement (reduction) in PASI score compared to baseline. | Weeks 16 and 52 |
| Percentage of patients with psoriatic arthritis (PsA) who achieved at least PASI 90 at Week 16 with secukinumab | PASI 90 response was defined as ≥ 90% improvement (reduction) in PASI score compared to baseline. | Week 16 |
| Percentage of patients with relapse event after treatment discontinuation | Up to 52 weeks |
| Length of remission period for patients with relapse, calculated from the last treatment date until relapse or starting recurrent symptom(s) or sign(s) | Up to 52 weeks |
| Percentage of patients achieving Dermatology Life Quality Index (DLQI) 0/1 at Week 52 | DLQI is a ten-item general dermatology disability index designed to assess healthrelated quality of life in adult participants with skin diseases such psoriasis. It is a selfadministered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) 1 ( a little) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. | Week 52 |